Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

Nature

Volumn 503, Issue 7475, 2013, Pages 277-280

  Shingai, Masashi ^a   Nishimura, Yoshiaki ^a   Klein, Florian ^b   Mouquet, Hugo ^c   Donau, Olivia K ^a   Plishka, Ronald ^a   Buckler White, Alicia ^a   Seaman, Michael ^d   Piatak, Michael ^e   Lifson, Jeffrey D ^e   Dimitrov, Dimiter ^f   Nussenzweig, Michel C ^b,f   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c INSTITUT PASTEUR   (France)

^d HARVARD MEDICAL SCHOOL   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 1074 MONOCLONAL ANTIBODY; 3BNC117 MONOCLONAL ANTIBODY; CD4 ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PEPTIDE FRAGMENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; PLASMA; PRIMATE; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; IMMUNOLOGY; MACACA; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; MUS; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; BINDING SITES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNOTHERAPY; MACACA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VIRAL LOAD; VIREMIA;

EID: 84887627657     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12746     Document Type: Article

References (30)

1. Mascola, J. R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
2. Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921-18925 (2012).
3. Nishimura, Y. et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer ofhigh-titered neutralizing antibodies. J. Virol. 76, 2123-2130 (2002).
4. Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
5. Mehandru, S. et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81, 11016-11031 (2007).
6. Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431-438 (1999).
7. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Med. 11, 615-622 (2005).
8. Burton, D. R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
9. Huang, J. et al. Broadandpotent neutralization of HIV-1byagp41-specific human antibody. Nature 491, 406-412 (2012).
10. Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
11. Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Struct. Mol. Biol. 20, 796-803 (2013).
12. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
13. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
14. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
15. Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516-8526 (2012).
16. Nishimura, Y. et al. Generation of the pathogenic R5-tropic simian/human immunodeficiencyvirusSHIVAD8byserialpassaginginrhesus macaques. J. Virol. 84, 4769-4781 (2010).
17. Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. Natl Acad. Sci. USA 109, 19769-19774 (2012).
18. Walker, L. M. et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl Acad. Sci. USA 108, 20125-20129 (2011).
19. Sadjadpour, R. et al. Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 87, 8798-8804 (2013).
20. Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268-E3277 (2012).
21. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
22. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
23. Diskin, R. et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210, 1235-1249 (2013).
24. Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA. http://dx.doi.org/10.1073/pnas.1315295110 (2013).
25. Igarashi, T. et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med. 5, 211-216 (1999).
26. Keele, B. F. et al. Low-doserectal in oculation of rhesusmacaques by SIVsm E660or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206, 1117-1134 (2009).
27. Endo, Y. et al. Short-and long-term clinical outcomes in rhesus monkeys inoculated withahighly pathogenic chimeric simian/human immunodeficiency virus. J. Virol. 74, 6935-6945 (2000).
28. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
29. Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protocols Immunol. Ch. 12, Unit 12 11 (2005).
30. Polis, M. A. et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 358, 1760-1765 (2001).